Over the past 7 years, our research has been featured in 54 peer-reviewed articles published in academic journals and 48 conference publications. These include the following.
· (2018) Amyloid deposits imaged in post-mortem retinas using polarimetry predict the severity of a post-mortem brain-based diagnosis of AD. Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
· (2017) The relationship between amyloid in the retina and a brain-based post mortem diagnosis of Alzheimer’s disease. Alzheimer’s and Dementia: Journal of the Alzheimer’s Association.
· (2016) Amyloid as a biomarker of Alzheimer’s disease in post-mortem retinas in human and dog models of Alzheimer’s disease. Alzheimer’s and Dementia: Journal of the Alzheimer’s Association.
· (2016) Mapping the birefringence of amyloid deposits found in retinas in association with Alzheimer’s disease. Optical Society of America, Frontiers in Optics.
Proof of concept presentations were made at both of the most recent Alzheimer’s Association International Conferences – AAIC 2016 in Toronto and AAIC 2017 in London. In 2016, the AAIC highlighted our early detection research at a press conference and our solution was featured by news journalists from around the world.
Our research team has made a number of important contributions to high-resolution optical imaging of individual cells in the retina of the human eye. Our research, conducted at the University of Waterloo, uses and develops leading edge technologies supporting 'the eye is a window to the brain'.
Dr. Campbell was amongst the first researchers to identify Amyloid beta in the retina with high frequency in Alzheimer's patients.
She postulated that Amyloid deposits in the retina interact with polarized light in such a way as to be visible, and proceeded to make proof of the concept.
She then succeeded in developing a system and methodology using polarized light to detect the presence and measure the amount of Amyloid beta in the neural layer of the retina, with a degree of accuracy that matches the much costlier and radiation exposed PET scans.
Over the past few years, over $2.5 million in research grants have been received. These have enabled the technology to be successfully developed along with validating studies using human living eyes to be conducted.
LumeNeuro is now meeting with investors to commercialize this screening test for early detection of Alzheimer’s disease. We are also interested in licensing agreements with pharmaceutical companies for use in the development of Alzheimer’s drugs.